Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Allakos Inc. (ALLK) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/21/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF ALLAKOS INC."
08/18/2023 4 Alta Partners Management VIII, LLC (10% Owner) has filed a Form 4 on Allakos Inc.
Txns: Disposed of 6,448,053 shares @ $0
Acquired 1,463,378 shares @ $0
Disposed of 1,463,378 shares @ $0
08/18/2023 SC 13D/A Alta Partners VIII, L.P. reports a 3.5% stake in Allakos Inc.
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results SAN CARLOS, Calif., August 9, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2023. Recent Allakos Events • Presented preclinical data at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2023 highlighting lirentelimab and AK006 mechanisms of action and inhibitory activity on IgE and non-IgE activated mast cells. Key findings of the presentation included: o AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib. o Siglec-6 interacts with ..."
08/03/2023 4 Thomas Dolca (Director) has filed a Form 4 on Allakos Inc.
Txns: Granted 154,786 options to buy @ $5.55, valued at $859.1k
08/03/2023 4 Sutherland Everett Rand (Director) has filed a Form 4 on Allakos Inc.
Txns: Granted 154,786 options to buy @ $5.55, valued at $859.1k
08/03/2023 3 Sutherland Everett Rand (Director) has filed a Form 3 on Allakos Inc.
08/03/2023 3 Thomas Dolca (Director) has filed a Form 3 on Allakos Inc.
08/02/2023 8-K Quarterly results
06/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition – AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib – – AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activation – SAN CARLOS, Calif., June 12, 2023 -- Allakos Inc. , a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced an oral presentation at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2023. The presentation highlighted preclinical data detailing lirentelimab and AK006 mechanism ..."
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 144 Form 144 - Report of proposed sale of securities:
05/30/2023 4 Walker Paul Edward (Director) has filed a Form 4 on Allakos Inc.
Txns: Granted 86,762 options to buy @ $4.81, valued at $417.3k
05/30/2023 4 Ladd Amy L (Director) has filed a Form 4 on Allakos Inc.
Txns: Granted 86,762 options to buy @ $4.81, valued at $417.3k
05/30/2023 4 James Steven P (Director) has filed a Form 4 on Allakos Inc.
Txns: Granted 86,762 options to buy @ $4.81, valued at $417.3k
05/30/2023 4 JANNEY DANIEL (Director) has filed a Form 4 on Allakos Inc.
Txns: Granted 86,762 options to buy @ $4.81, valued at $417.3k
05/30/2023 4 Andreatta Robert E (Director) has filed a Form 4 on Allakos Inc.
Txns: Granted 86,762 options to buy @ $4.81, valued at $417.3k
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports First Quarter 2023 Financial Results SAN CARLOS, Calif., May 9, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Recent Allakos Events • Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis during the first quarter of 2023. • Continued enrollment of a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria during the first quarter of 2023. Upcom..."
04/20/2023 ARS Form ARS - Annual Report to Security Holders:
04/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
04/17/2023 8-K Quarterly results
03/09/2023 4 Alexander Robert (CEO) has filed a Form 4 on Allakos Inc.
Txns: Paid exercise price by delivering 9,143 shares @ $6.4, valued at $58.5k
Paid exercise price by delivering 66,274 shares @ $6.24, valued at $413.5k
03/08/2023 4 Tomasi Adam (President) has filed a Form 4 on Allakos Inc.
Txns: Paid exercise price by delivering 57,467 shares @ $5.34, valued at $306.9k
03/06/2023 4 Radford Harlan Baird (CFO) has filed a Form 4 on Allakos Inc.
Txns: Paid exercise price by delivering 33,907 shares @ $5.75, valued at $195k
03/06/2023 4 Paterson Craig A. (Chief Medical Officer) has filed a Form 4 on Allakos Inc.
Txns: Paid exercise price by delivering 26,615 shares @ $5.83, valued at $155.2k
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results SAN CARLOS, Calif., March 6, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab and AK006. Recent Allakos Events • Initiated a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria in the third quarter of 2022. • Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patien..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy